Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05216380
Other study ID # H00021562
Secondary ID 1K12HL138049-01
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2021
Est. completion date June 12, 2022

Study information

Verified date August 2023
Source University of Massachusetts, Worcester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Cancer survivors have a greater risk of cardiovascular disease (CVD) and have low physical activity levels. Physical inactivity is one modifiable risk factor for CVD, and increased physical activity has shown a cardioprotective effect on lowering CVD risk. The objective of ActivityLink is to use an electronic referral (e-referral) implementation program for clinic staff to refer survivors to an in-person and a virtual physical activity program. Methods: Participants in this study will include clinic staff and patients. Investigators will first conduct interviews with clinic staff and patients, followed by usability testing of a referral system with staff. The study team will then beta-test two rounds of testing using Plan, Do, Study, Act (PDSA) Cycles for clinic staff to refer patients in the clinic. Quantitative data and qualitative interviews will be collected following each PDSA cycle, with refinements made based on feedback. Outcomes: The proposed study addresses a critical need to implement physical activity referrals into routine cancer survivorship visits.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date June 12, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria for Aim 1a: - Medical providers who are 1) Are a current UMass Cancer Clinic patient navigator, oncologist, radiologist, or cardiologist 2) Consent to participate in the study. - Program leaders who are 1) In charge of implementing evidence-based physical activity program for cancer patients/survivors (LIVESTRONG at the Y); 2) Consent to participate in the study. - Patients who receive treatments at the UMass Cancer Clinics who are 1) Are at least 18 years of age; and 2) Consent to participate in the study. Exclusion Criteria for Aim 1a: - Medical providers who are 1) Not currently employed at UMass Memorial Health (UMH), 2) Not involved in direct treatment of care coordination of cancer patients - Program leaders who are 1) not involved in the implementation of an evidence-based physical activity program for cancer survivors - Patients who are 1) Unable or unwilling to provide informed consent; 2) <18 years of age. Inclusion Criteria for Aim 1b: - Participants for Aim 1b are eligible if they are: 1) Are a UMass Cancer Clinic patient navigator; and 2) Consent to participate in the study. Inclusion criteria for Aim 2: - Clinic staff who 1) Are a current UMass Cancer Clinic staff delivering care to patients 2) Consent to participate in the study. - Program leaders who are 1) In charge of implementing evidence-based physical activity program that clinic staff refer cancer patients/survivors to (LIVESTRONG at the Y and FitCancer); 2) Consent to participate in the study. - Patients who receive a physical activity program referral during their survivorship care planning from UMass Cancer Clinics who are 1) Are at least 18 years of age; and 2) Consent to participate in the study. Exclusion Criteria for Aim 2: - Clinic staff who are 1) Not currently employed at UMass, 2) Not implementing patient treatment of care coordination of cancer patients - Program leaders who are 1) not involved in the implementation of an evidence-based physical activity program clinic staff refer cancer survivors to - Patients who are 1) Unable or unwilling to provide informed consent; and 2) <18 years of age

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
ActivityLink
ActivityLink is an implementation program using: Didactic and experiential training sessions for clinic staff to conduct referrals Secure electronic referral webform to refer patients using their email address and phone number Messaging sent to the patient and provider that they have been referred to a program Clinic visual cues (flyers and paper prescription pad) to reinforce referrals Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot

Locations

Country Name City State
United States University of Massachusetts Chan Medical School Worcester Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
University of Massachusetts, Worcester National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Patients Referred Using the Secure Webform The number of patients referred using the secure webform 12 weeks from launch of referrals (baseline)
Secondary Proportion of Eligible Clinic Staff Who Enroll Proportion of eligible clinic staff who enroll 12 weeks from launch of referrals (baseline)
Secondary Acceptability Qualitative feedback from enrolled clinic staff and referred survivors, using PRISM framework to assess barriers to implementation and program referrals At study completion, within 3 months of referral completion
Secondary Proportion of Referred Patients Who Enroll in Programs Proportion of referred patients who enroll in programs At study completion, within 3 months of referral completion
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases